These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11281378)

  • 1. High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial.
    Pérez-Gracia JL; Colomer R; Ruiz-Casado A; Arcediano A; Tornamira MV; Gómez-Martin C; Valentin V; Mendiola C; Cortés-Funes H; Hornedo J
    Bone Marrow Transplant; 2001 Jan; 27(2):117-23. PubMed ID: 11281378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
    Pérez-Gracia JL; Colomer R; Esteban E; Barceló R; Benavides M; Puertas J; Arcediano A; Tornamira MV; Valentín V; Muñoz A; Cortés-Funes H; Hornedo J
    Cancer; 2001 Nov; 92(10):2508-16. PubMed ID: 11745183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
    Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
    Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
    Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M
    Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies.
    Ellis ED; Williams SF; Moormeier JA; Kaminer LS; Bitran JD
    Bone Marrow Transplant; 1990 Dec; 6(6):439-42. PubMed ID: 1982927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer.
    Recchia F; De Fillipis S; Piccinini M; Rea S
    Anticancer Res; 2003; 23(5b):4141-7. PubMed ID: 14666615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.
    Genre D; Viens P; Bertucci F; Chabannon C; Gravis G; Braud AC; Camerlo J; Houvenaeghel G; Moutardier V; Goncalvez A; Protière C; Bardou VJ; Maraninchi D
    Bone Marrow Transplant; 2002 Jun; 29(11):881-6. PubMed ID: 12080351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
    Lee CK; de Magalhaes-Silverman M; Hayashi M; Schlueter A; Strauss RG; Hohl RJ; Gingrich RD
    Bone Marrow Transplant; 2002 Apr; 29(8):647-52. PubMed ID: 12180108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
    Sparano JA; Robert N; Silverman P; Lazarus H; Malik U; Venkatraj U; Sarta C
    J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].
    Qiu HY; Wu DP; Sun AN; Chang WR; Jin ZM; Miao M; Tang XW; Shen YM; Fu ZZ
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):462-5. PubMed ID: 15555260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.
    Budd GT; Atiba J; Silver RT; Palmer G; Armstrong S; Otto K; Presant C
    J Cancer Res Clin Oncol; 1999; 125(8-9):500-4. PubMed ID: 10480343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
    Talbot SM; Westerman DA; Grigg AP; Toner GC; Wolf M; Bishop J; McKendrick J; Zalcberg J; Levi J; Fox RM; Green MD
    Ann Oncol; 1999 Aug; 10(8):907-14. PubMed ID: 10509151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.